June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
The NO donor, isorbide-5-mononitrate alone or combined with timolol, latanoprost or dorzolamide ameliorates intraocular pressure and ocular hemodynamic in an experimental model of glaucoma in rabbits
Author Affiliations & Notes
  • Francesco Impagnatiello
    Nicox Research Institute, Bresso, Milan, Italy
  • Barbara Giambene
    Eye Clinic, University of Florence, Florence, Italy
  • Francesca Fabrizi
    Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
  • Elena Bastia
    Nicox Research Institute, Bresso, Milan, Italy
  • Fernando Galassi
    Eye Clinic, University of Florence, Florence, Italy
  • Emanuela Masini
    Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
  • Footnotes
    Commercial Relationships Francesco Impagnatiello, Nicox Research Institute (C); Barbara Giambene, None; Francesca Fabrizi, Nicox Research Institute (F); Elena Bastia, Nicox Research Institute (E); Fernando Galassi, None; Emanuela Masini, Nicox Research Institute (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4449. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Francesco Impagnatiello, Barbara Giambene, Francesca Fabrizi, Elena Bastia, Fernando Galassi, Emanuela Masini; The NO donor, isorbide-5-mononitrate alone or combined with timolol, latanoprost or dorzolamide ameliorates intraocular pressure and ocular hemodynamic in an experimental model of glaucoma in rabbits. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4449.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Ocular hypertension is the major risk factor in glaucoma. However, other risk factors of vascular origin have been identified. Nitric oxide (NO) signalling seems to play a crucial role, being involved in the regulation of aqueous humour (AH) outflow and ocular hemodynamics. We studied the effects on intraocular pressure (IOP) and retrobulbar hemodynamic following 28 days daily topical dosing with isosorbide-5-mononitrate (ISMN, 0.5%), either alone or combined with the β-blocker, timolol (0.5%), the prostaglandin F2α agonist, latanoprost (0.05%) and the carbonic anhydrase inhibitor, dorzolamide (2%) in an experimental rabbit model of glaucoma.

Methods: Ocular hypertension was obtained by the injection of carbomer (0.1%, 0.1ml) in the anterior chamber of New Zealand White rabbits. IOP was measured using a Tono-Pen. Retrobulbar hemodynamics of the ophthalmic artery was assessed using Color Doppler Imaging. The examinations were performed prior to drug treatment (baseline) and 7, 14, 21 and 28 days thereafter. Furthermore, cGMP content in AH was monitored throughout the experimental period to address the extent of NO signalling pathway activation.

Results: On average, IOP rose from 13.4±2.0 mmHg at baseline to 38.9±4.0 mmHg one week post carbomer injection and remained stable thereafter. Timolol, latanoprost, and dorzolamide lowered IOP (on average 20-30%, p<0.001) at all time points post dose. ISMN, albeit less effectively, also lowered IOP in this model and the effect was additive when co-administered with timolol, latanoprost or dorzolamide. Similarly, carbomer increased the resistivity index of the ophthalmic artery from 0.48±0.02 (basal) to 0.62±0.03 (one week post carbomer, p<0.05). ISMN reversed this effect when administered alone or combined with timolol, latanoprost or dorzolamide. Consistent with the above findings, NO markers i.e. cGMP and nitrate were increased in AH following ISMN treatment.

Conclusions: ISMN by re-establishing physiologic NO signaling in target ocular tissues, ameliorates the effects of current treatments on IOP and ocular hemodynamics.

Keywords: 617 nitric oxide • 436 blood supply • 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×